Wedbush lowered the firm’s price target on Voyager Therapeutics to $8 from $10 and keeps a Neutral rating on the shares. On the heels of the AGCST meeting, the Q1 Voyager update was largely as anticipated with no change to all major development timelines, the firm says. Most notable, Voyager announced the IND for antitau antibody VY-TAU01 was cleared with the first healthy volunteer expected to be dosed in the single-ascending dose portion of the study by mid-2024, Wedbush adds.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VYGR:
- Voyager Therapeutics Reports First Quarter 2024 Financial and Operating Results
- VYGR Earnings this Week: How Will it Perform?
- Voyager Therapeutics presents data for Tracer platform
- Voyager Therapeutics Presents Data for Second-Generation, TRACER™-Generated Capsids and CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting
- Voyager Therapeutics Announces First Quarter 2024 Conference Call and Webcast